New Study Finds Abrocitinib May Be Better Value Than Upadacitinib for UK Eczema Patients
Published
A new economic study suggests that abrocitinib, a medicine used to treat severe eczema, may be a more cost-effective choice than upadacitinib for patients in the United Kingdom. The research was published on Bioengineer.org and looked at how the two treatments compare in terms of cost and health benefits for the National Health Service (NHS).
Eczema is a long-term skin condition that causes itching, redness and dry, cracked skin. For people with moderate or severe cases, treatment options can be expensive, and healthcare budgets are often under pressure. Both abrocitinib and upadacitinib belong to a group of medicines called JAK inhibitors, which work by reducing inflammation inside the body. Because of this, doctors and health officials want to understand which option gives the best value for money.
According to the economic model, abrocitinib was found to be more cost-effective than upadacitinib in the UK setting. The researchers used computer-based calculations to estimate the costs of treatment and the health gains for patients over time. Their results suggest that, based on the assumptions used, abrocitinib could offer a better balance between cost and benefit. However, the findings are based on a model, so they do not show the full picture of how each medicine performs in everyday clinical practice.
The study does not change current treatment guidelines on its own. Decisions about which medicine to prescribe are usually made by specialists and the National Institute for Health and Care Excellence (NICE), which considers both clinical evidence and cost. Patients with eczema who have questions about their treatment are advised to speak with their GP or dermatology team. Further research and official reviews will be needed before any changes are made to NHS prescribing.
Sources: Bioengineer.org
More United Kingdom news
- New UK-EU Trade Deal Described as "Transformational" for Northern Ireland
- UK Public Sector Turns to AI: What It Could Mean for Tech Companies
- Scotland Celebrates Its Best Technology Talent at 2026 Awards
- Prime Minister Confirms UK Will Follow EU Rules Again Under New Deal
- Scotland Confirms Glass Will Not Be Included in Deposit Return Scheme
- Andy Burnham Profiled as Labour Leader and Prime Minister
- Trainee Doctors in Obstetrics and Gynaecology Report Rising Overwork, Regulator Says
- No UK Health News in Today's Source Material